Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study

NCT06155422 is registered in ClinicalTrials.gov with Gang Chen (101199) as lead sponsor.

NCT NCT06155422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06155422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study
Lead sponsor
Gang Chen (101199)
Phase
Observational
Overall status
Not yet recruiting
Start date
November 30, 2023
Completion date
November 30, 2027
Enrollment
670 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic cervical cancer